logo
  

GSK : Preclinical Data Show Sotrovimab Retains Activity Against Omicron Mutations

GlaxoSmithKline plc. (GSK,GSK.L) and Vir Biotechnology Inc. (VIR) said preclinical data demonstrated that sotrovimab, an investigational monoclonal antibody, retains activity against key mutationsof the new Omicron SARS-CoV-2 variant (B.1.1.529), including those found in the binding site of sotrovimab.

The companies said that the data will be confirmed by further in vitro pseudo-virus testing. They plans to provide an update on it by the end of 2021.

GSK and Vir are also partnering to investigate the use of sotrovimab in uninfected immunocompromised adults to determine whether sotrovimab can prevent symptomatic COVID-19 infection.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Home improvement company Lowe's and pet retailer Petco Health and Wellness Co. are set to launch a pilot store-in-store program whereby a total home solution will be offered to customers by bringing home improvement as well as pet care products, services and expertise together under the same roof. Chevron Corporation (CVX) reported fourth quarter profit of $5.1 billion or $2.63 per share, compared to a loss of $665 million or $0.33 per share, previous year. The company's U.S. upstream operations earned $2.97 billion, compared to $101 million, a year ago. The company said the improvement was primarily... While reporting financial results for the fourth quarter on Friday, Colgate-Palmolive Co. (CL) initiated its earnings and sales growth guidance for the full-year 2022. For fiscal 2022, the company now expects earnings per share to grow in double-digit percentage and adjusted earnings per share growth...
Follow RTT